Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          HHS Search block
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              Blog
                              Draft National Strategy for Vector-Borne Diseases: We Want to Hea
 Navigate to:
  Categories
    Coronavirus (12)
        Health IT (13)
        Fraud (1)
        Grants and Contracts (1)
        Research (5)
        Prevention and Wellness (21)
        Health Data (6)
        Holidays and Observances (17)
        Global Health (4)
        Public Health and Safety (28)
        HIPAA (4)
        Programs for Families and Children (6)
        Americans with Disabilities Act (1)
        Mental Health and Substance Abuse (1)
        Vaccines (1)
        HHS Administrative (4)
        LGBT (1)
        Emergency Preparedness and Response (1)
        Drug Pricing (5)Text resize icon

                    




Draft National Strategy for Vector-Borne Diseases: We Want to Hear from You








  
  
    

  
      
**December 13, 2022**
                |
        By:  James    Berger, Senior Advisor for Blood and Tissue Policy, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services, Daniel     Desautels  PhD, ORISE Fellow, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services and Kristen    Honey  PhD, PMP, Chief Data Scientist

  
**Summary:**
  





HHS seeks input on its draft National Public Health Strategy for the Prevention and Control of Vector-Borne Diseases in Humans by 12/21/22.


      After years of progress by the 14-member Tick-Borne Disease Working Group (TBDWG) and community-driven Lyme Innovation, HHS and partners are ushering in a new era for Lyme and tickborne-disease solutions with renewed focus on implementation. In consultation with the TBDWG, the Office of the Assistant Secretary for Health (OASH) and CDC are leading the development of a whole-of-government strategy for vector-borne diseases—with emphasis on implementation.

In November 2022, HHS published the DRAFT National Strategy with a request for information (“RFI”), entitled *Input on the National Public Health Strategy for the Prevention and Control of Vector-Borne Diseases in Humans* (Federal Register notice). Spanning both civilian agencies and defense departments, the National Strategy will:

Assess gaps and any unnecessary duplication of federally funded programs.
	Identify strategic goals to address such diseases.
	Coordinate programs and federal activities to address such diseases.Seventeen agencies and divisions worked with HHS to develop this DRAFT National Strategy, per the Kay Hagan Tick Act (P.L. 116-94) passed by Congress in 2019, because vector-borne diseases are a serious public health problem. Examples of vector-borne diseases include the Zika virus, West Nile virus, and tickborne diseases, including Lyme disease. These are diseases carried by mosquitoes, ticks, fleas, and biting insects.

Lyme disease is the fastest-growing vector-borne disease in the United States, accounting for over 70% of all vector-borne disease domestically. Lyme disease is the most common tickborne disease, yet there are at least 20 different infections that are transmitted by ticks in the United States. The CDC estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease each year. Due to climate change, habitat loss, and other land-use changes, humans face greater risk today than historically because of increased exposure risks to tick bites that transmit vector-borne diseases.

The DRAFT National Strategy RFI includes an informational crosswalk that maps the TBDWG 2018 Report and TBDWG 2020 Report recommendations to Congress with the goals and strategic priorities of the DRAFT *National Strategy* (see pages 70844–70848; entitled the *HHS Tick-Borne Disease Working Group Cross Walk*). It shows where and how the implementation is happening across HHS, CDC, NIH, FDA, CMS and federal agencies—with a one-to-one mapping between the DRAFT National Strategy and TBDWG recommendations made to HHS and Congress.

U.S. government will improve the National Strategy with your input. RFI responses will help HHS to finalize the National Strategy, due to Congress by December 2023.

**Please** **submit your RFI comments on Regulations.gov****before 12:00pm midnight Eastern Time (ET) on December 21, 2022.**

Solutions to Lyme and vector-borne diseases will require all of us, and the National Strategy will be a future roadmap for implementing U.S. solutions. Implementation of the National Strategy will be enhanced by collaboration, both within and outside of government. Partnerships, like the LymeX Innovation Accelerator, can expedite progress.

Collaboration opportunities include community-driven Lyme Innovation events, placing Lyme patients and the lived experience at the center of the innovation process. For example, the HHS Health+ (pronounced “health plus”) collaboration synthesized almost 700 hours of research with diverse communities to co-create the Health+ Lyme Disease Human-Centered Design Report (2021, 123 pages). Other engagement avenues exist through the LymeX public-private partnership. For example, the LymeX Diagnostics Prize recently awarded $1 million dollars, announcing 10 Phase 1 winners developing Lyme disease diagnostics that each received $100,000 for breakthrough technologies. The LymeX Diagnostics Prize is a multi-year innovation challenge with ambitious plans for 2023, including 2023 LymeX events open to the public. Also in 2023, HHS expects to host Lyme and vector-borne-disease workshops and potentially also roundtables and virtual meetups.

For continued progress, HHS believes that ongoing, robust engagement with the patient-led community is essential. Multiple pathways will ensure continued transparency and collaborative communications between the federal government and external stakeholders.

If you have ideas to improve the DRAFT National Strategy, please share them with HHS. Submit your RFI comments on Regulations.gov before 12:00am midnight Eastern Time (ET) on December 21, 2022.
  Posted In:
  Health ITSign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up







  Subscribe to RSS
    

      Receive latest updates

                    
  


Related Blog Posts
    

      Empowering Transformation - Inaugural Digital Experience Expo
  

Long COVID Innovation in Action! Meet the Long COVID Healthathon Winners
  

OCIO Embracing Diversity: A Celebration of Cultures through Food Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​ Disclaimer Policy: Links with this icon () mean that you are leaving the HHS website. The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
                  Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
                  You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
                  HHS is not responsible for Section 508 compliance (accessibility) on private websites. For more information on HHS's web notification policies, see Website Disclaimers.
 Continue
                  Go back